A phase I trial of everolimus in combination with 5-FU/LV, mFOLFOX6 and mFOLFOX6 plus panitumumab in patients with refractory solid tumors

PURPOSE: This phase I study investigated the safety, dose limiting toxicity, and efficacy in three cohorts all treated with the mTOR inhibitor everolimus that was delivered 1) in combination with 5-fluourouracil with leucovorin (5-FU/LV), 2) with mFOLFOX6 (5-FU/LV + Oxaliplatin), and 3) with mFOLFOX...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cancer Chemother Pharmacol
Main Authors: McRee, Autumn J., Davies, Janine M., Sanoff, Hanna G., Goldberg, Richard M., Bernard, Stephen, Dees, E. Claire, Keller, Kimberly, Ivanova, Anastasia, O'Neil, Bert H.
Formato: Artigo
Idioma:Inglês
Publicado em: 2014
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4517671/
https://ncbi.nlm.nih.gov/pubmed/24819684
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00280-014-2474-0
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados